Certara, Inc. (NASDAQ:CERT) Shares Purchased by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA grew its stake in shares of Certara, Inc. (NASDAQ:CERT) by 4.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,083,940 shares of the company’s stock after buying an additional 182,042 shares during the period. Massachusetts Financial Services Co. MA owned 2.54% of Certara worth $43,494,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in CERT. Venturi Wealth Management LLC increased its position in Certara by 839.1% during the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after purchasing an additional 2,509 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of Certara by 20.9% during the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock worth $56,000 after purchasing an additional 822 shares during the last quarter. ANTIPODES PARTNERS Ltd grew its holdings in shares of Certara by 204.7% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company’s stock worth $58,000 after buying an additional 3,656 shares in the last quarter. KBC Group NV raised its position in shares of Certara by 64.1% in the fourth quarter. KBC Group NV now owns 7,998 shares of the company’s stock valued at $85,000 after buying an additional 3,125 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of Certara by 442.2% during the fourth quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock valued at $90,000 after buying an additional 6,868 shares during the period. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Trading Down 2.4 %

NASDAQ CERT opened at $9.55 on Friday. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of -47.75, a PEG ratio of 9.29 and a beta of 1.64. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. Certara, Inc. has a one year low of $9.21 and a one year high of $19.18. The company’s 50 day moving average price is $12.14 and its 200 day moving average price is $11.41.

Wall Street Analysts Forecast Growth

Several research firms have commented on CERT. Stephens reaffirmed an “overweight” rating and issued a $17.00 target price on shares of Certara in a research note on Thursday, February 27th. TD Cowen began coverage on Certara in a research note on Thursday, February 27th. They issued a “buy” rating and a $16.00 target price for the company. Barclays raised their price target on Certara from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Friday, February 28th. Finally, William Blair reaffirmed a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $15.83.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.